KYMR / Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2023 Earnings Call Transcript November 2, 2023 8:00 AM ET Company Participants Justine Koenigsberg - VP, I more_horizontal

Kymera Therapeutics, Inc. (KYMR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong more_horizontal

The heavy selling pressure might have exhausted for Kymera Therapeutics, Inc. (KYMR) as it is technically in oversold territory now. In addition to th more_horizontal

Kymera Therapeutics, Inc. (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings more_horizontal

Kymera Therapeutics has nine programs in its pipeline. It has a collaboration with Sanofi on its lead therapy IRAK-4. more_horizontal

Kymera Therapeutics' valuation is difficult to estimate due to lack of positive net income, making it a poor buy. The company received FDA Orphan Drug more_horizontal

Perella Weinberg Partners (PWP) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants Bruce Jacobs - CFO Nello Mainolfi - Fo more_horizontal

Kymera produced solid-looking phase 1 data, but Pfizer's problems in the space, along with some safety issues, hurt its stock. When partner Sanofi pro more_horizontal